Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
Extensive legal experience with private and public biotech companies including Biogen,
“Simona’s deep legal experience and proven track record in the life sciences industry will be critical as we execute on our vision to enable a new class of drugs in the microbiome field,” said
“With the recent activity and interest in the microbiome field, it has become clear that Vedanta has shown great promise in pioneering defined bacterial consortia as a new class of therapeutics,” said
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what it believes to be the world’s biggest library of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies and cGMP-compliant manufacturing of oral live biotherapeutic candidates containing pure, clonally derived bacterial consortia in powdered form. Vedanta Biosciences was founded by
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005266/en/
Investors and Media
+1 617 835 9304
Chris.Brinzey@westwicke.com
Source: Vedanta Biosciences